Comparative Pharmacology
Head-to-head clinical analysis: BAXDELA versus CIPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAXDELA versus CIPRO.
BAXDELA vs CIPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BAXDELA (delafloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, leading to inhibition of DNA replication and transcription.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription, leading to bacterial cell death.
Oral: 450 mg (as single tablet) twice daily for 5 days. Intravenous: 450 mg once daily (over 3 hours) or 300 mg twice daily (over 1 hour) for 5 days.
Ciprofloxacin 500 mg PO q12h or 400 mg IV q12h for uncomplicated infections; 750 mg PO q12h or 400 mg IV q8h for severe/complicated infections.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours in healthy adults; may be prolonged in patients with renal impairment (up to 20 hours in severe renal impairment).
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCiprofloxacin + Digitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCiprofloxacin + Deslanoside
"Ciprofloxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCiprofloxacin + Acetyldigitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 3-5 hours (normal renal function), extended to 8-10 hours in mild-to-moderate renal impairment (CrCl 30-50 mL/min) and up to >10 hours in severe impairment (CrCl <30 mL/min); half-life in elderly may be 5-8 hours due to reduced clearance.
Renal (approximately 65% of dose as unchanged drug) and fecal (approximately 20% as metabolites and unchanged drug). Biliary excretion is minimal.
Renal (50-70% unchanged via glomerular filtration and tubular secretion); biliary/fecal (15-20%, primarily as metabolites); small amount metabolized to 4 metabolites (oxo-, sulfo-, and desethylene-ciprofloxacin).
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic